To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib
in combination with L-ASP, vincristine, and prednisone (LVP) in patients with
relapsed-and-refractory (R/R) early T precursor acute lymphocytic leukemia (ETP-ALL). Once
determined, the purpose of this study will be to determine the efficacy of ruxolitinib in
combination with LVP in patients with R/R ETP-ALL.